Type1diabetes study: Tirzepatide
Official title Tirzepatide Use in People With Obesity and Type 1 Diabetes
ClinicalTrials.gov ID: NCT07096908
What this study is testing
What is Tirzepatide?
An investigational once‑weekly injectable medicine being studied as a potential treatment for obesity in people with type 1 diabetes. It is designed to activate both GIP and GLP‑1 receptors, which can influence appetite and blood‑sugar regulation.
Also referred to as Mounjaro.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether tirzepatide helps people lose weight. It also checks if the drug is safe for people with type 1 diabetes.
- Who it's for
- You may be able to join if you have type 1 diabetes and are also living with obesity.
- What's involved
- You would be picked by chance, like a coin toss, to get the drug or usual care. Neither you nor the team knows which one you get.
- Time commitment
- The study involves regular visits to check your weight and health over time.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 21 and older
You may be able to join if
- Informed consent obtained before any trial-related activities.
- Male or female, adults.
- Documented diagnosis of T1DM (per ADA 2024definition/criteria) for at least 1 year before screening visit with C-peptide level of less than 0.01nm/L.
- Body mass index (BMI) ≥ 27.0 kg/m2
- History of at least one self-reported unsuccessful dietary effort to lose body weight.
You likely can't join if
- Glycated hemoglobin (HbA1c) ≥86 mmol/mol (10%) as measured by the central laboratory at screening.
- Treatment with a glucagon-like peptide-1 receptor agonist within 180 days before screening.
- Preproliferative or proliferative retinopathy
- Experienced diabetic ketoacidosis within 6 months of screening visit.
- Experienced severe hypoglycemia (Level 3) within 6 months of screening visit.
- A self-reported change in body weight \>5 kg (11 lbs) within 90 days before screening irrespective of medical records.
See the full eligibility criteria
- Informed consent obtained before any trial-related activities.
- Male or female, adults.
- Documented diagnosis of T1DM (per ADA 2024definition/criteria) for at least 1 year before screening visit with C-peptide level of less than 0.01nm/L.
- Body mass index (BMI) ≥ 27.0 kg/m2
- History of at least one self-reported unsuccessful dietary effort to lose body weight.
- Must be using a Continuous Glucose Monitoring (CGM) device for at least 2 months before the screening visit and be willing to wear a CGM device for the duration of the study.
- Glycated hemoglobin (HbA1c) ≥86 mmol/mol (10%) as measured by the central laboratory at screening.
- Treatment with a glucagon-like peptide-1 receptor agonist within 180 days before screening.
- Preproliferative or proliferative retinopathy
- Experienced diabetic ketoacidosis within 6 months of screening visit.
- Experienced severe hypoglycemia (Level 3) within 6 months of screening visit.
- A self-reported change in body weight \>5 kg (11 lbs) within 90 days before screening irrespective of medical records.
- Treatment with any medication for the indication of obesity within the past 90 days before screening.
- Previous or planned (during the trial period) obesity treatment with surgery or a weight-loss device. However, the following are allowed: (1) liposuction and/or abdominoplasty, if performed \>1 year before screening
- Uncontrolled thyroid disease, defined as thyroid stimulating hormone \>6.0 mIU/L or \<0.4 mIU/L as measured by the central laboratory at screening.
- History of major depressive disorder within 2 years before screening.
- Diagnosis of other severe psychiatric disorder (e.g. schizophrenia, bipolar disorder).
- A Patient Health Questionnaire-9 score of ≥15 at screening.
- A lifetime history of a suicidal attempt.
- Suicidal behavior within 30 days before screening.
- Suicidal ideation corresponding to type 4 or 5 on the Columbia-Suicide Severity Rating Scale within the past 30 days before screening.
- Use of non-herbal Chinese medicine or other non-herbal local medicine with unknown/unspecified content within 90 days before screening.
- Presence of acute pancreatitis within the past 180 days prior to the day of screening.
- History or presence of chronic pancreatitis.
- Calcitonin ≥100 ng/L as measured by the central laboratory at screening.
- Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma.
- Renal impairment measured as estimated glomerular filtration rate value of \<15 mL/min/1.73m2 as defined by KDIGO 2012 by the central laboratory at screening.
- History of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed.
- Any of the following: myocardial infarction, stroke, hospitalization for unstable angina, or transient ischemic attack within the past 60 days prior to screening.
- Subject presently classified as being in New York Heart Association Class IV.
- Surgery scheduled for the duration of the trial, except for minor surgical procedures, in the opinion of the investigator.
- Known or suspected abuse of alcohol or recreational drugs.
- Known or suspected hypersensitivity to trial product(s) or related products.
- Previous participation in this trial. Participation is defined as signed informed consent.
- Participation in another clinical trial within 90 days before screening.
- Other subject(s) from the same household participating in any semaglutide trial.
- Female who is pregnant, breast-feeding, or intends to become pregnant, or is of child-bearing potential and not using a highly effective contraceptive method.
- Any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the subject's safety or compliance with the protocol.
The study team makes the final eligibility decision.
Where it is enrolling
- Kuwait City, Sharq, Kuwait
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 21 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Kuwait City, Sharq, Kuwait. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.